To the Editor.—
Pentoxifylline (Trental) has been used worldwide since 1972 for the treatment of intermittent claudication. In 1984, the US Food and Drug Administration approved the release of this medication for use in the United States. This drug lowers the blood viscosity and improves erythrocyte flexibility. These effects allow increased blood flow to ischemic tissues.In November 1984, a 46-year-old man who had severe atrophie blanche with leukocytoclastic vasculitis for five years brought me a newspaper clipping about pentoxifylline therapy. His problem had been studied and a biopsy performed. The condition was only partially controlled with the administration of oral prednisone. The disease resulted in a multitude of small painful ulcers with crusts and scaling that extended from the foot almost to his knees.Pentoxifylline therapy was begun with a dosage of 400 mg twice a day for three days, then the dosage was changed to three tablets per
Sauer GC. Pentoxifylline (Trental) Therapy for the Vasculitis of Atrophie Blanche. Arch Dermatol. 1986;122(4):380–381. doi:10.1001/archderm.1986.01660160030012
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: